PHAXIAM Therapeutics S.A. (0QSS.L)

2,9246 -0,0687 (-2,30%) Börsenschluss: 05:52PM BST

PHAXIAM Therapeutics S.A.

60 Avenue Rockefeller
Bâtiment Adénine
Lyon 69008
France
33 4 78 74 44 38
https://www.phaxiam.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 68

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Eric Soyer Ph.D.	Deputy CEO, Deputy GM, CFO & COO	379,72k	N/A	1966
Dr. Jérôme Bailly Pharm.D.	Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person	247,91k	N/A	1979
Mr. Thibaut du Fayet	Chief Executive Officer	N/A	N/A	1968
Ms. Céline Breda	Chief Technology Officer	N/A	N/A	1971
Ms. Cindy Fevre	Chief Scientific Officer	N/A	N/A	N/A
Naomi Eichenbaum	Director Investor Relations	N/A	N/A	N/A
Ms. Anne-Cécile Fumey	Vice President of Human Resources	N/A	N/A	1976
Ms. Karine Charton Ph.D.	Chief Business Officer	N/A	N/A	N/A
Dr. Pascal Birman M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Frederique Vieville	Chief Regulatory Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Corporate Governance

PHAXIAM Therapeutics S.A.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.